James R. Tobin Sells 15,040 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 15,040 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the transaction, the director now owns 205,171 shares in the company, valued at $21,836,349.53. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

TransMedics Group Stock Performance

Shares of TMDX traded up $3.55 during trading hours on Friday, hitting $127.99. The company’s stock had a trading volume of 1,543,089 shares, compared to its average volume of 765,449. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The business has a 50 day simple moving average of $85.54 and a two-hundred day simple moving average of $76.85. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $129.66. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. The firm’s quarterly revenue was up 132.9% on a year-over-year basis. On average, equities analysts expect that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on TMDX shares. JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a report on Wednesday. Oppenheimer raised their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. Canaccord Genuity Group increased their price target on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, TD Cowen lifted their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $119.00.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently modified their holdings of the company. RiverPark Advisors LLC raised its position in shares of TransMedics Group by 361.1% in the first quarter. RiverPark Advisors LLC now owns 6,082 shares of the company’s stock worth $450,000 after buying an additional 4,763 shares in the last quarter. Fidelis Capital Partners LLC bought a new position in TransMedics Group in the 1st quarter worth about $35,000. BNP Paribas Financial Markets raised its holdings in shares of TransMedics Group by 35.1% in the 1st quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock valued at $1,286,000 after acquiring an additional 4,518 shares in the last quarter. Oak Ridge Investments LLC boosted its position in shares of TransMedics Group by 59.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company’s stock valued at $1,351,000 after acquiring an additional 6,813 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after purchasing an additional 21,737 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.